News Center - News Center - 上海诗健生物科技有限公司

LATEST NEWS

Escugen Partners with GFK to Empower Innovative Drug Target Discovery and Accelerate Pipeline Layout via AI + Big Data

2026-02-09

Recently, Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") and Shanghai GFK Pharmaceutical Engineering Technology Co., Ltd. (hereinafter referred to as "GFK") officially signed a cooperation agreement. Under the agreement, GFK will leverage its independently developed AI Bio-Big Data Intelligent Platform to provide Escugen with accurate and efficient target discovery services, helping Escugen expand the boundaries of innovative R&D. In turn, Escugen will give full play to its strengths in innovative drug R&D to accelerate the new drug development process.

Explore more

ADC Development Rising Star Escugen Biotechnology Completes $100 Million Series A+ Financing to Continue Advancing Innovative ADC Pipeline

In May 2023, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced the completion of a $100 million Series A+ financing round.

2023-05-31
Recruitment Ongoing for Phase I/II Study of ESG401 in Locally Advanced/Metastatic Solid Tumors

The "Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ESG401 in Patients with Locally Advanced/Metastatic Solid Tumors" (Study Number: ESG401-101), sponsored by Shanghai Escugen Biotechnology Co., Ltd., has been successfully launched. The study has received approval from the National Medical Products Administration (Clinical Trial Notification Number: 2021LP01074) and is currently recruiting participants at multiple top-tier hospitals across the country.

2023-04-10

<13 14 15 16 17 18 19 20 21 22 >